We're kicking off the 43rd Annual Healthcare Conference this morning, and I couldn't be more delighted to introduce Vertex's CEO, Reshma Kewalramani. She's going to come on stage to give a ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a decline, ending the day at $439.62 which represents a decrease of $-0.11 or -0.03% from the prior close of $439.73. The stock opened at $438.73 and ...

Vertex could win approval for suzetrigine early, too. Keith Speights has positions in Vertex Pharmaceuticals. The Motley Fool ...

Vertex Pharmaceuticals' suzetrigine showed lackluster ... After acknowledging the market disappointment toward Phase II data, Vertex CEO Reshma Kewalramani said that future studies need to be ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated ... Democrats, and the Executive) act in unison then, “when you have that kind of come together over ...

The CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating the ongoing row over the price of cystic fibrosis drugs in England.

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $422 which represents a slight increase of $5.04 or 1.21% from the prior close of $416.96. The stock opened at $422.73 ...